- Home
- DBX vs TFX Comparison
DBX vs TFX Comparison
Compare DBX & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBX
- TFX
- Stock Information
- Founded
- DBX 2007
- TFX 1943
- Country
- DBX United States
- TFX United States
- Employees
- DBX N/A
- TFX N/A
- Industry
- DBX Computer Software: Prepackaged Software
- TFX Medical/Dental Instruments
- Sector
- DBX Technology
- TFX Health Care
- Exchange
- DBX Nasdaq
- TFX Nasdaq
- Market Cap
- DBX 7.5B
- TFX 8.3B
- IPO Year
- DBX 2018
- TFX N/A
- Fundamental
- Price
- DBX $26.56
- TFX $137.81
- Analyst Decision
- DBX Buy
- TFX Hold
- Analyst Count
- DBX 4
- TFX 9
- Target Price
- DBX $27.67
- TFX $193.88
- AVG Volume (30 Days)
- DBX 4.4M
- TFX 1.7M
- Earning Date
- DBX 05-08-2025
- TFX 05-01-2025
- Dividend Yield
- DBX N/A
- TFX 0.98%
- EPS Growth
- DBX 6.57
- TFX N/A
- EPS
- DBX 1.40
- TFX 1.48
- Revenue
- DBX $2,548,200,000.00
- TFX $3,047,324,000.00
- Revenue This Year
- DBX N/A
- TFX $3.37
- Revenue Next Year
- DBX $0.28
- TFX $4.13
- P/E Ratio
- DBX $18.99
- TFX $93.54
- Revenue Growth
- DBX 1.86
- TFX 2.45
- 52 Week Low
- DBX $20.68
- TFX $128.55
- 52 Week High
- DBX $33.33
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- DBX 44.73
- TFX 35.19
- Support Level
- DBX $26.49
- TFX $137.79
- Resistance Level
- DBX $27.67
- TFX $140.98
- Average True Range (ATR)
- DBX 0.67
- TFX 3.22
- MACD
- DBX 0.28
- TFX 1.41
- Stochastic Oscillator
- DBX 65.42
- TFX 38.44
About DBX Dropbox Inc.
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.